VIA Pharmaceuticals, Inc. (NASDAQ: VIAP)

VIA Pharmaceuticals, Inc. (NASDAQ: VIAP) is focused on developing a pipeline of small-molecule drugs designed to target a substantial, but unmet medical need – reducing inflammation in the blood vessel wall. This is known as an underlying cause of atherosclerosis and its complications, including heart attack and stroke. VIA-2291, the company’s lead drug candidate, is currently in a number of Phase 2 clinical trials in patients with cardiovascular disease. For further information, visit the Company’s web site at www.viapharmaceuticals.com.